Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

Bellicum Pharmaceuticals logo

About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)

Advanced Chart

Key Stats

Today's Range
$0.07
$0.09
50-Day Range
$0.07
$0.10
52-Week Range
$0.06
$1.31
Volume
6,059 shs
Average Volume
22,874 shs
Market Capitalization
$726,570.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Stock News Headlines

Tesla Shares Soar After Trump Win (Act Now)
Are you ready to see why Tesla might be the biggest opportunity on the market today? Right now, Tesla stock is at a critical juncture, and Lance believes it’s primed for explosive growth. That’s why he’s giving away his eBook, The Bullish Case for Tesla, for FREE—but only for a limited time.
Bellicum Pharmaceuticals Inc BLCM
Futura Medical plc (FAMDF)
BLCM - Bellicum Pharmaceuticals, Inc.
See More Headlines

BLCM Stock Analysis - Frequently Asked Questions

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its quarterly earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $1.15. The biopharmaceutical company earned $0.70 million during the quarter.

Bellicum Pharmaceuticals shares reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Bellicum Pharmaceuticals (BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), NVIDIA (NVDA), CyberArk Software (CYBR), Gilead Sciences (GILD) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
8/11/2021
Today
2/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-24,970,000.00
Pretax Margin
-1,492.40%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$0.23 per share

Miscellaneous

Free Float
8,716,000
Market Cap
$726,570.00
Optionable
Not Optionable
Beta
1.39

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:BLCM) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners